Abstract: The invention provides a compound according to formula (I) or a tautomer thereof, wherein R1, R2, R3, W1, W2, W3, A, X and Y are as defined in the specification. The compounds are potent inhibitors of the serine/threonine kinase, TAK1. The present invention further provides: a pharmaceutical composition comprising a compound of formula (I) and at least one pharmaceutically acceptable excipient; a compound of formula (I) for use as a medicament (for example for the treatment or prophylaxis of a condition selected from cancer, inflammatory diseases, autoinflammatory diseases and autoimmune diseases); and a method of treating or preventing a disease or disorder comprising administering a pharmaceutically effective amount of a compound of formula (I) to a subject in need thereof.

Abstract: The invention provides the compound 5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-quinoline-3-carboxamide potassium salt. It is considered to have the structure of formula (I): The compound is provided in solid (eg crystalline or amorphous) or aqueous solution form. Pharmaceutical compositions comprising the compound are also provided. The compound finds use as a medicament, in particular for the treatment or prophylaxis of an inflammatory bowel disease.

Abstract: The invention provides a compound according to formula (I); Formula (I) as more particularly defined in the specification, or a pharmaceutically acceptable salt or solvate thereof for use in the treatment or prophylaxis of an inflammatory bowel disease. The invention also provides pharmaceutical compositions comprising a compound of the invention and methods of treatment using a compound of the invention.